2011
Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing
April MD, Chiosi JJ, Paltiel AD, Sax PE, Walensky RP. Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing. Journal Of General Internal Medicine 2011, 26: 661-667. PMID: 21286837, PMCID: PMC3101973, DOI: 10.1007/s11606-011-1637-5.Peer-Reviewed Original ResearchConceptsPotential survival gainsSurvival gainHIV testingDiagnosis rateAnnual HIV incidenceProportion of HIVUndiagnosed HIV prevalenceAnnual HIV diagnosis ratesHIV diagnosis ratesHIV incidenceHIV prevalenceEarly diagnosisHIVDisease controlLYGSurveillance dataAdult personsConsentConsent methodsPersonsPatientsConsent lawsBackgroundAlthoughDesignWeObjectiveToThe Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa
Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E, April MD, Bassett IV, Morris BL, Freedberg KA, Paltiel AD. The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: 26-35. PMID: 21068674, PMCID: PMC3005842, DOI: 10.1097/qai.0b013e3181fb8f24.Peer-Reviewed Original ResearchConceptsVoluntary HIV screeningQuality-adjusted life yearsHIV screeningLife yearsHIV case detectionHIV testing costsTest acceptance rateIncremental cost-effectiveness ratioSubstantial clinical benefitIncidence/prevalenceOne-time screeningDirect medical costsLife expectancyQuality-adjusted life expectancyCost-effectiveness ratioAntiretroviral therapyAnnual incidenceClinical benefitHIV prevalenceClinical impactCase detectionMedical costsCare ratesHIVTest acceptance
2010
Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis
Martin EG, Paltiel AD, Walensky RP, Schackman BR. Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis. Value In Health 2010, 13: 893-902. PMID: 20950323, PMCID: PMC2999642, DOI: 10.1111/j.1524-4733.2010.00763.x.Peer-Reviewed Original ResearchMeSH KeywordsAIDS SerodiagnosisForecastingHealth Care CostsHumansMass ScreeningMedical AssistanceProspective Payment SystemUnited StatesConceptsHIV screeningEarly treatment goalsNew HIV casesFrequency of screeningBudget impact analysisTotal budget increasesHIV careAnnual incidenceHIV casesHIV prevalenceCDC estimatesUS CentersTreatment goalsBudget impactTreatment programDisease controlHIVTest characteristicsTreatment costsFinancial burdenCareScreeningSmall proportionProgram savingsFund careRoutine HIV Screening in France: Clinical Impact and Cost-Effectiveness
Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD. Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. PLOS ONE 2010, 5: e13132. PMID: 20976112, PMCID: PMC2956760, DOI: 10.1371/journal.pone.0013132.Peer-Reviewed Original ResearchConceptsQuality-adjusted life monthsCost-effectiveness ratioQuality-adjusted life yearsGeneral populationRoutine HIVHIV prevalenceFrequent screeningLife expectancyAnnual HIV incidenceRoutine HIV screeningUndiagnosed HIV prevalenceHigh-risk groupHIV testing behaviorsInjection drug usersFrench general populationEpidemiology of infectionHIV screeningVoluntary HIVHIV infectionHIV testingAnnual screeningHIV incidenceMean ageHIV screenClinical impact
2009
HIV Testing Rates and Outcomes in a South African Community, 2001-2006: Implications for Expanded Screening Policies
April MD, Walensky RP, Chang Y, Pitt J, Freedberg KA, Losina E, Paltiel AD, Wood R. HIV Testing Rates and Outcomes in a South African Community, 2001-2006: Implications for Expanded Screening Policies. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 51: 310-316. PMID: 19582895, PMCID: PMC3209660, DOI: 10.1097/qai.0b013e3181a248e6.Peer-Reviewed Original ResearchConceptsART initiation ratesHIV testing ratesAntiretroviral treatmentTesting ratesHIV testingWorld Health Organization stageProvider-initiated testingFirst-time testersWorld Health Organization recommendationsMonths of eligibilityHigh-prevalence populationsHealth care facilitiesProportion of clientsMedian CD4Testing registersAnnual incidenceHIV servicesLate diagnosisPrevalence populationsTreatment trendsCare facilitiesStage distributionScreening policiesPatient recordsPopulation testing
2007
Cost-Effectiveness of HIV Testing and Treatment in the United States
Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-Effectiveness of HIV Testing and Treatment in the United States. Clinical Infectious Diseases 2007, 45: s248-s254. PMID: 18190295, PMCID: PMC2365915, DOI: 10.1086/522546.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS SerodiagnosisCost-Benefit AnalysisDiagnostic ServicesHIV InfectionsHumansMiddle AgedUnited StatesConceptsHIV testingVoluntary human immunodeficiency virus (HIV) testingHuman immunodeficiency virus (HIV) testingRoutine HIV testingVoluntary HIV testingLower cost-effectiveness ratioCost-effectiveness ratioCost-effectiveness studiesHealth care settingsPublic health importanceHealth care interventionsCost-effectiveness analysisImmunodeficiency syndromeRisk factorsCare interventionsUS CentersCare settingsVirus testingHealth effectivenessHealth importanceDisease controlRecent evidenceHIVNew guidelinesUnited States
2005
Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral
Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral. Medical Decision Making 2005, 25: 321-329. PMID: 15951459, DOI: 10.1177/0272989x05276955.Peer-Reviewed Original ResearchMeSH KeywordsAIDS SerodiagnosisComputer SimulationContinuity of Patient CareCost-Benefit AnalysisCounselingDecision Support TechniquesHIV InfectionsHumansInvestmentsMass ScreeningModels, StatisticalPatient Acceptance of Health CarePrevalenceProbabilityQuality-Adjusted Life YearsReferral and ConsultationResource AllocationSensitivity and SpecificityUnited StatesConceptsCost-effectiveness ratioScreening programUndiagnosed HIV prevalenceHealth screening programHIV testing servicesHIV testingHIV counselingHIV prevalenceLimited screening resourcesClinical impactAppropriate careQALYTesting pathwayTesting servicesScreening resourcesPathway outcomesOptimal targetingCarePathwayEarly stagesHIVReferralAdditional peopleFollowLater stages